ACTIVE CLINICAL TRIALS AT SANA RESEARCh
ADVANCE-2 Trial: People with Agitation Due to Alzheimer's Dementia
As Alzheimer's dementia progresses, up to 75% of people will develop symptoms of agitation or aggression which can hinder their care. Currently there is only one FDA approved drug to treat agitation due to dementia called Rexulti. Rexulti is an atypical anti-psychotic, a class of drug that does slightly increase the risk of sudden death.
Axsome Therapeutics is sponsoring the ADVANCE-2 Study to evaluate the effects of dextrometorphan/buproprion to reduce agitation. This combination does not increase the risk of death.
Sana Research continues to screen and enroll people into the ADVANCE-2 Study. Please note: subjects must have a family member caregiver who lives with the subject and is willing to participate with the study protocol. Please contact us or call 703-717-7764 if you would like more information.
REWIND-LB: A Trial for Patient with Mild Dementia
with Lewy Bodies (DLB)
The 2nd most common form of degenerative dementia is Lewy Body Dementia. This form of dementia is notable not only for memory loss, but people can experience visual hallucinations, tremors, movement disorders, difficulty sleeping, and instability of blood pressure.
Currently, there is no FDA approved target therapy. The REWIND-LB study is evaluating the effects of neflamapimod in reducing symptoms of DLB.
Enrollment has closed, but we hope there will be continued research and development into new therapies.